119 related articles for article (PubMed ID: 27401863)
1. Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY.
van der Lely AJ; Jönsson P; Wilton P; Åkerblad AC; Cara J; Ghigo E
Eur J Endocrinol; 2016 Oct; 175(4):239-45. PubMed ID: 27401863
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients).
Barraud S; Caron P; Raingeard I; Lefebvre H; Raverot G; Cortet-Rudelli C; Desailloud R; Henocque R; Brault Y; Brue T; Chanson P; Delemer B
Ann Endocrinol (Paris); 2021 Dec; 82(6):582-589. PubMed ID: 34256010
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.
Salvatori R; Maffei P; Webb SM; Brue T; Loftus J; Valluri SR; Gomez R; Wajnrajch MP; Fleseriu M
Pituitary; 2022 Jun; 25(3):420-432. PubMed ID: 35022929
[TBL] [Abstract][Full Text] [Related]
4. ACROSTUDY: Status Update on 469 Patients.
Brue T
Horm Res; 2009 Jan; 71 Suppl 1():34-8. PubMed ID: 19153503
[TBL] [Abstract][Full Text] [Related]
5. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
[TBL] [Abstract][Full Text] [Related]
6. Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy.
Brue T; Lindberg A; Jan van der Lely A; Akerblad AC; Koltowska-Häggström M; Gomez R; Droste M; Hey-Hadavi J; Strasburger CJ; Camacho-Hübner C
Endocrine; 2019 Mar; 63(3):563-572. PubMed ID: 30474822
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
8. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
Fleseriu M; Führer-Sakel D; van der Lely AJ; De Marinis L; Brue T; van der Lans-Bussemaker J; Hey-Hadavi J; Camacho-Hubner C; Wajnrajch MP; Valluri SR; Palladino AA; Gomez R; Salvatori R
Eur J Endocrinol; 2021 Aug; 185(4):525-538. PubMed ID: 34342594
[TBL] [Abstract][Full Text] [Related]
9. Pegvisomant in acromegaly: a multicenter real-life study in Argentina.
Basavilbaso NXG; Ballarino MC; Bruera D; Bruno OD; Chervin AB; Danilowicz K; Fainstein-Day P; Fidalgo SG; Frigeri A; Glerean M; Guelman R; Isaac G; Katz DA; Knoblovits P; Librandi F; Montes ML; Mallea-Gil MS; Manavela M; Mereshian P; Moncet D; Pignatta A; Rogozinsky A; Sago LR; Servidio M; Spezzi M; Stalldecker G; Tkatch J; Vitale NM; Guitelman M
Arch Endocrinol Metab; 2019 Aug; 63(4):320-327. PubMed ID: 31460622
[TBL] [Abstract][Full Text] [Related]
10. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.
Franck SE; Korevaar TIM; Petrossians P; Daly AF; Chanson P; Jaffrain-Réa ML; Brue T; Stalla GK; Carvalho D; Colao A; Hána V; Delemer B; Fajardo C; van der Lely AJ; Beckers A; Neggers SJCMM
Eur J Endocrinol; 2017 Apr; 176(4):421-431. PubMed ID: 28100630
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
Neggers SJ; Franck SE; de Rooij FW; Dallenga AH; Poublon RM; Feelders RA; Janssen JA; Buchfelder M; Hofland LJ; Jørgensen JO; van der Lely AJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3644-52. PubMed ID: 24937542
[TBL] [Abstract][Full Text] [Related]
12. Brazilian multicenter study on pegvisomant treatment in acromegaly.
Boguszewski CL; Huayllas MKP; Vilar L; Naves LA; Ribeiro-Oliveira Junior A; Soares BS; Czepielewski MA; Abucham J; Correa-Silva SR; Bronstein MD; Jallad RS; Duarte FG; Musolino NR; Kasuki L; Gadelha MR
Arch Endocrinol Metab; 2019 Jul; 63(4):328-336. PubMed ID: 31365632
[TBL] [Abstract][Full Text] [Related]
13. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
15. Successful use of weekly pegvisomant administration in patients with acromegaly.
Higham CE; Thomas JD; Bidlingmaier M; Drake WM; Trainer PJ
Eur J Endocrinol; 2009 Jul; 161(1):21-5. PubMed ID: 19411301
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
[TBL] [Abstract][Full Text] [Related]
17. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.
Parkinson C; Burman P; Messig M; Trainer PJ
J Clin Endocrinol Metab; 2007 Jan; 92(1):190-5. PubMed ID: 17077131
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.
Tritos NA; Chanson P; Jimenez C; King D; Jönsson PJ; Klibanski A; Biller BM
Eur J Endocrinol; 2017 Feb; 176(2):213-220. PubMed ID: 27932529
[TBL] [Abstract][Full Text] [Related]
19. How to improve effectiveness of pegvisomant treatment in acromegalic patients.
Ragonese M; Grottoli S; Maffei P; Alibrandi A; Ambrosio MR; Arnaldi G; Bianchi A; Puglisi S; Zatelli MC; De Marinis L; Ghigo E; Giustina A; Maffezzoni F; Martini C; Trementino L; Cannavo S
J Endocrinol Invest; 2018 May; 41(5):575-581. PubMed ID: 29080965
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.
Bianchi A; Valentini F; Iuorio R; Poggi M; Baldelli R; Passeri M; Giampietro A; Tartaglione L; Chiloiro S; Appetecchia M; Gargiulo P; Fabbri A; Toscano V; Pontecorvi A; De Marinis L
J Exp Clin Cancer Res; 2013 Jun; 32(1):40. PubMed ID: 23799893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
